Showing results (81-90 of 91) with videos related to

Sort By:
Pageof 10
Plos One|February 25, 2022
Genome-wide analysis of sucrose synthase family in soybean and their expression in response to abiotic stress and seed developmentMuhammad Zulfiqar Ahmad, Hafiz Ishfaq Ahmad, Asma Gul, et al.
Cureus|August 14, 2023
Enhancing Radiation Safety Culture: Investigating the Mediating Role of Awareness Among Orthopedic Doctors and Operation Theatre AssistantsJunaid Khan, Bilal Khalid, Muhammad Zulfiqar Abbasi, et al.
European Journal of Cancer (Oxford, England : 1990)|June 15, 2021
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort studyMaryam Soleimani, Kevin Zou, Katherine Sunderland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2016
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based ChemotherapySharlene Gill, Yoo-Joung Ko, Christine Cripps, et al.
PLOS Global Public Health|April 9, 2025
A narrative review of the pathophysiology of sepsis in sub-Saharan Africa: Exploring the potential for corticosteroid therapyPhoebe Gruccio, William S Girard, Amelia D Badipour, et al.
Biomed Research International|June 19, 2020
Adaptive Molecular Evolution of AKT3 Gene for Positive Diversifying Selection in MammalsFarmanullah, Seyed Mahdi Hosseini, Aixin Liang, et al.
Cancer Discovery|January 26, 2018
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Gillian Vandekerkhove, Daniel Khalaf, et al.
Oncotarget|March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionMatti Annala, Sinja Taavitsainen, Daniel J Khalaf, et al.
The Lancet. Oncology|November 16, 2019
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trialDaniel J Khalaf, Matti Annala, Sinja Taavitsainen, et al.
Pageof 10